Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC

CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028

Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research